技术指标
指标
数值
方向
MACD(12,26,9)
-0.044
中性
RSI(14)
42.778
中性
STOCH(KDJ)(9,3,3)
7.736
超卖
ATR(14)
0.177
高波动
CCI(14)
-100.290
卖出
Williams %R
96.673
超卖
TRIX(12,20)
0.255
卖出
StochRSI(14)
0.000
超卖
搜索
InMed Pharmaceuticals Inc
INM添加自选
1.460USD
-0.040-2.67%
收盘 07-31 16:00（美东）报价延迟15分钟
4.09M总市值
亏损市盈率 TTM
关键数据
1.550今开
1.560最高
258.49K成交量
亏损市盈率 TTM
--市盈率动
--股息TTM
9.22%换手率
1.500昨收
1.440最低
259.43K成交额
亏损市盈率静
0.43市净率
0.00%股息率 TTM
-85.12%ROA
7.98052周最高
1.00量比
-8.16M净利润
2.80M总股本
-2.1210每股收益TTM
0.94Beta
-112.65%ROE
0.57552周最低
7.97%振幅
15.97%毛利率
4.09M总市值
-0.79回报/风险
4.85%风险率
TradingKey InMed Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-07-31操作建议
InMed Pharmaceuticals Inc当前公司基本面数据相对非常健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名194/385位。机构持股占比非常高，中期看，股价处于上升通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
InMed Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
InMed Pharmaceuticals Inc亮点
亮点风险
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
业绩高增长
公司营业收入稳步增长，连续3年增长19.52%
业绩增长期
公司处于发展阶段，最新年度总收入4.94M美元
估值低估
公司最新PE估值-0.69，处于3年历史低位
机构减仓
最新机构持股320.11K股，环比减少12.00%
分析师目标
根据
0
位分析师
--
评级
--
目标均价
--
涨幅空间
InMed Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
技术指标
移动平均线
指标
数值
方向
MA5
1.590
卖出
MA10
1.623
卖出
MA20
1.615
卖出
MA50
1.586
卖出
MA100
1.162
买入
MA200
1.237
买入
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
InMed Pharmaceuticals Inc简介
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
公司代码INM
公司InMed Pharmaceuticals Inc
CEOAdams (Eric A)
网址https://www.inmedpharma.com/
公司股东
相关品种
热门品种
常见问题
InMed Pharmaceuticals Inc(INM)的当前股价是多少？
InMed Pharmaceuticals Inc(INM)的当前股价是 1.46。
InMed Pharmaceuticals Inc的股票代码是什么？
InMed Pharmaceuticals Inc的股票代码是INM。
InMed Pharmaceuticals Inc股票的52周最高点是多少？
InMed Pharmaceuticals Inc股票的52周最高点是7.98。
InMed Pharmaceuticals Inc股票的52周最低点是多少？
InMed Pharmaceuticals Inc股票的52周最低点是0.57。
InMed Pharmaceuticals Inc的市值是多少？
InMed Pharmaceuticals Inc的市值是4.09M。
InMed Pharmaceuticals Inc(INM)股票的每股收益（EPS TTM）是多少
InMed Pharmaceuticals Inc(INM)股票的每股收益（EPS TTM）是-8.36。